Drugs / Lopinavir/Ritonavir
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01601626 | Jul 2013 → Jan 2017 | HIV infectious disease, tuberculosis | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lopinavir/Ritonavir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01601626 ↗ |
| Route | Oral | “Two LPV 200 mg/RTV 50 mg fixed-dose combination tablets orally twice daily from entry to Week 72.” NCT01601626 ↗ |